Strides Pharma Unit Receives US Regulatory Approval For Antidepressant Medication

Strides Pharma Science said on Tuesday that its subsidiary has received approval from the US health regulator to market a generic antidepressant medication. The company's Singapore-based wholly-owned subsidiary, Strides Pharma Global Pte Ltd, has received approval for Fluoxetine Tabs (10 and 20 mg) from the U.S. Food & Drug Administration, the drug firm said in a regulatory filing.

The company's product is therapeutically equivalent to Eli Lilly's Prozac tablets.

As per IMS, Fluoxetine tablets have a market size of $23.9 million.

This approval further strengthens the company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a market size of $106 million, the Bengaluru based firm said.

Fluoxetine is used for the treatment of major depressive disorder and obsessive compulsive disorder among others.